196 related articles for article (PubMed ID: 21762735)
1. Human papillomavirus type 18 chimeras containing the L2/L1 capsid genes from evolutionarily diverse papillomavirus types generate infectious virus.
Bowser BS; Chen HS; Conway MJ; Christensen ND; Meyers C
Virus Res; 2011 Sep; 160(1-2):246-55. PubMed ID: 21762735
[TBL] [Abstract][Full Text] [Related]
2. Study of infectious virus production from HPV18/16 capsid chimeras.
Chen HS; Bromberg-White J; Conway MJ; Alam S; Meyers C
Virology; 2010 Sep; 405(2):289-99. PubMed ID: 20598725
[TBL] [Abstract][Full Text] [Related]
3. Infectious virions produced from a human papillomavirus type 18/16 genomic DNA chimera.
Meyers C; Bromberg-White JL; Zhang J; Kaupas ME; Bryan JT; Lowe RS; Jansen KU
J Virol; 2002 May; 76(10):4723-33. PubMed ID: 11967289
[TBL] [Abstract][Full Text] [Related]
4. L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
Okun MM; Day PM; Greenstone HL; Booy FP; Lowy DR; Schiller JT; Roden RB
J Virol; 2001 May; 75(9):4332-42. PubMed ID: 11287582
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
6. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
Schellenbacher C; Roden R; Kirnbauer R
J Virol; 2009 Oct; 83(19):10085-95. PubMed ID: 19640991
[TBL] [Abstract][Full Text] [Related]
7. Mutations in HPV18 E1^E4 Impact Virus Capsid Assembly, Infectivity Competence, and Maturation.
Biryukov J; Myers JC; McLaughlin-Drubin ME; Griffin HM; Milici J; Doorbar J; Meyers C
Viruses; 2017 Dec; 9(12):. PubMed ID: 29257050
[TBL] [Abstract][Full Text] [Related]
8. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Pastrana DV; Gambhira R; Buck CB; Pang YY; Thompson CD; Culp TD; Christensen ND; Lowy DR; Schiller JT; Roden RB
Virology; 2005 Jul; 337(2):365-72. PubMed ID: 15885736
[TBL] [Abstract][Full Text] [Related]
9. A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.
Huber B; Schellenbacher C; Jindra C; Fink D; Shafti-Keramat S; Kirnbauer R
PLoS One; 2015; 10(3):e0120152. PubMed ID: 25790098
[TBL] [Abstract][Full Text] [Related]
10. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
11. Cell surface-binding motifs of L2 that facilitate papillomavirus infection.
Yang R; Day PM; Yutzy WH; Lin KY; Hung CF; Roden RB
J Virol; 2003 Mar; 77(6):3531-41. PubMed ID: 12610128
[TBL] [Abstract][Full Text] [Related]
12. HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer.
Amaro-Filho SM; Pereira Chaves CB; Felix SP; Basto DL; de Almeida LM; Moreira MAM
Papillomavirus Res; 2018 Jun; 5():172-179. PubMed ID: 29649654
[TBL] [Abstract][Full Text] [Related]
13. Papillomavirus capsid proteins mutually impact structure.
Chen HS; Conway MJ; Christensen ND; Alam S; Meyers C
Virology; 2011 Apr; 412(2):378-83. PubMed ID: 21329956
[TBL] [Abstract][Full Text] [Related]
14. The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.
Holmgren SC; Patterson NA; Ozbun MA; Lambert PF
J Virol; 2005 Apr; 79(7):3938-48. PubMed ID: 15767396
[TBL] [Abstract][Full Text] [Related]
15. Treatment with Radix Euphorbiae Ebracteolatae Significantly Decreases the Expression of E6 and L1, and Increases the Expression of p53 and Rb in HPV18-infected Human Foreskin Keratinocytes.
He X; He X; Xu P; Yang L; Ma X; Li W; Zhang H
Curr Mol Med; 2019; 19(1):20-31. PubMed ID: 30813877
[TBL] [Abstract][Full Text] [Related]
16. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Roden RB; Greenstone HL; Kirnbauer R; Booy FP; Jessie J; Lowy DR; Schiller JT
J Virol; 1996 Sep; 70(9):5875-83. PubMed ID: 8709207
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.
Karanam B; Gambhira R; Peng S; Jagu S; Kim DJ; Ketner GW; Stern PL; Adams RJ; Roden RB
Vaccine; 2009 Feb; 27(7):1040-9. PubMed ID: 19095032
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
19. Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes.
Conway MJ; Cruz L; Alam S; Christensen ND; Meyers C
PLoS One; 2011 Feb; 6(2):e16405. PubMed ID: 21346798
[TBL] [Abstract][Full Text] [Related]
20. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry.
Bienkowska-Haba M; Williams C; Kim SM; Garcea RL; Sapp M
J Virol; 2012 Sep; 86(18):9875-87. PubMed ID: 22761365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
